➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Moodys
Mallinckrodt
Medtronic
Johnson and Johnson

Last Updated: June 12, 2021

DrugPatentWatch Database Preview

Claims for Patent: 10,010,585

« Back to Dashboard

Summary for Patent: 10,010,585
Title:Methods of treating vestibular schwannoma and reducing hearing or neurite loss caused by vestibular schwannoma
Abstract: Methods to reduce the proliferation of vestibular schwannoma (VS) cells and/or provide neuroprotection to reduce the risk of sensorineural hearing loss (SNHL), vestibular dysfunction and facial nerve paralysis in subjects with VS. The methods can include one or more of decreasing TNF-.alpha. activity or expression; decreasing NF-.kappa.B expression or activity; decreasing COX-2 expression or activity; administering FGF2; decreasing HGF expression or activity; or decreasing c-Met expression or activity.
Inventor(s): Stankovic; Konstantina (Boston, MA), Dilwali; Sonam (Dallas, TX)
Assignee: Massachusetts Eye and Ear Infirmary (Boston, MA)
Application Number:14/741,332
Patent Claims:1. A method of treating a subject having vestibular schwannoma, the method comprising identifying a subject having a vestibular schwannoma and administering to the ear of the subject a therapeutically effective amount of a TNF.alpha. inhibitor by direct delivery into the inner ear.

2. A method of reducing the rate of vestibular schwannoma tumor growth in a subject, the method comprising identifying a subject having a vestibular schwannoma and administering to the ear of the subject a therapeutically effective amount of a TNF.alpha. inhibitor by direct delivery into the inner ear.

3. The method of claim 1, wherein the TNF.alpha. inhibitor is selected from the group consisting of: adalimumab, infliximab, golimumab, etanercept, and certolizumab.

4. The method of claim 1, wherein the local administration is injection through the ear drum.

5. The method of claim 2, wherein the local administration is direct delivery into the inner ear.

Details for Patent 10,010,585

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Get Started Free Massachusetts Eye and Ear Infirmary (Boston, MA) 2034-06-16 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Get Started Free Massachusetts Eye and Ear Infirmary (Boston, MA) 2034-06-16 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Get Started Free Massachusetts Eye and Ear Infirmary (Boston, MA) 2034-06-16 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Get Started Free Massachusetts Eye and Ear Infirmary (Boston, MA) 2034-06-16 RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Get Started Free Massachusetts Eye and Ear Infirmary (Boston, MA) 2034-06-16 RX search
Centocor Ortho Biotech Inc SIMPONI golimumab INJECTABLE; INJECTION 125289 001 2009-04-24   Get Started Free Massachusetts Eye and Ear Infirmary (Boston, MA) 2034-06-16 RX Orphan search
Janssen Biotech SIMPONI ARIA golimumab INJECTABLE; INJECTION 125433 001 2013-07-18   Get Started Free Massachusetts Eye and Ear Infirmary (Boston, MA) 2034-06-16 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
McKesson
Johnson and Johnson
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.